Journal
STEM CELL REPORTS
Volume 4, Issue 3, Pages 473-488Publisher
CELL PRESS
DOI: 10.1016/j.stemcr.2015.01.007
Keywords
-
Categories
Funding
- Medical Research Council and British Heart Foundation [G0902170]
- UK Regenerative Medicine Platform
- Leukaemia Lymphoma Research
- BBSRC
- Wellcome Trust
- University of Manchester
- MRC [G0902170, MR/K026666/1] Funding Source: UKRI
- Medical Research Council [MR/K026666/1, G0902170] Funding Source: researchfish
Ask authors/readers for more resources
Mesenchymal progenitor cells have great therapeutic potential, yet incomplete characterization of their cell-surface interface limits their clinical exploitation. We have employed subcellular fractionation with quantitative discovery proteomics to define the cell-surface interface proteome of human bone marrow mesenchymal stromal/stemcells (MSCs) and human umbilical cord perivascular cells (HUCPVCs). We compared cell-surface-enriched fractions from MSCs and HUCPVCs (three donors each) with adult mesenchymal fibroblasts using eight-channel isobaric-tagging mass spectrometry, yielding relative quantification on >6,000 proteins with high confidence. This approach identified 186 upregulated mesenchymal progenitor biomarkers. Validation of 10 of these markers, including ROR2, EPHA2, and PLXNA2, confirmed upregulated expression in mesenchymal progenitor populations and distinct roles in progenitor cell proliferation, migration, and differentiation. Our approach has delivered a cell-surface proteome repository that now enables improved selection and characterization of human mesenchymal progenitor populations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available